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Abstract 
The fat mass and obesity associated gene (FTO) was placed centre stage when 
common intronic variants within the gene were robustly associated with human 
obesity.  
Murine models of perturbed Fto expression have shown effects on body weight and 
composition. However, a clear understanding of the link between FTO intronic 
variants and FTO activity has remained elusive. 
Two recent reports now indicate that obesity associated SNPs appear functionally 
connected not with FTO but with two neighbouring genes; IRX3 and RPGRIP1L. 
We review these new findings and consider the implications for future analysis of 
GWAS hits. 
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Introduction 
When first cloned in 1999, Fto was postulated to have a role in programmed cell death and 
development. It was identified in the study of the “fused toe” (Ft) mouse, a model organism 
created by insertional mutagenesis that had a 1.6 Mb deletion on chromosome 8 (van der 
Hoeven et al., 1994). Mice heterozygous for the Ft mutation developed fusion of the first to 
fourth toes of the forelimbs and thymic hyperplasia (Peters et al., 1999). This deletion 
eliminated six genes (Peters et al., 2002), three members of the Iroquois gene family (Irx3, 
Irx5 and Irx6) which form the IrxB cluster, as well as three other genes (Fts, Ftm and Fto) 
which at the time were poorly characterised. Fts was initially called “Ft1” being the first of 
the three to be identified: the second proved to be an elusive sequence to characterise  
technically so was labelled the Fantom (Ftm);  the third gene was named 'Fatso' (Fto) 
because of its large size (Fischer et al., 2008). 
Setting a theme which plays throughout the studies of Fto biology, subsequent studies of 
the Ft mouse were taken up in trying to determine which of the affected genes in the larger 
deleted locus were responsible for the component parts of the diverse phenotypes seen in 
the animal. Further, these initially mysterious genes underwent name changes to reflect 
evolving knowledge.  Ftm was found to be a novel basal body protein of cilia involved in 
Hedgehog (Hh) signalling (Vierkotten et al., 2007).  Sequence analysis revealed Ftm to be 
highly homologous to RPGRIP1 (retinitis pigmentosa GTPase regulator interacting protein 1, 
a gene encoding a protein with a role in photoreceptor cells of the eye) and it was renamed 
Rpgrip1-like (Rpgrip1l). In mice inactivation of Rpgrip1l causes a multi- organ syndromic 
phenotype with  cerebral, renal and hepatic defects (Vierkotten et al., 2007), while  
mutations in RPGRIP1L are the cause of a group of developmental disorders such as Joubert 
syndrome type B and Meckel syndrome (Delous et al., 2007). 
With the coming of age of technologically advanced genetic association studies, Fto 
underwent a more subtle but no less significant name change, with the roots of the labelling 
acronym reflecting its new association with obesity and metabolism. 
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A star is born 
In the first half of 2007, three independent studies demonstrated strong association 
between genetic variance within FTO and human obesity. The gene name morphed into 
“FaT mass and Obesity associated” and the metabolic community had, at last, an example of 
common genetic variance with robust evidence of association with obesity in the general 
population. 
The Frayling study initially set out to search for type 2 diabetes mellitus susceptibility genes. 
In doing so they identified a common variant in the FTO gene that did indeed predispose to 
diabetes but through an effect on body mass index (BMI). This effect on BMI was driven 
entirely through fat mass and, although not detectable at birth, was fully present by the age 
of 7 years and persisted through adulthood (Frayling et al., 2007). The major signal for 
association with BMI was a cluster of SNPs in the first intron of FTO. All BMI-associated SNPs 
were highly correlated with each other but SNP rs9939609, having the highest genotyping 
success rate, was studied further. The 16% of adults who were homozygous for the risk 
allele (A) weighed close to 3 kilograms more and had 1.67-fold increased odds of obesity 
when compared with those not inheriting a risk allele (Frayling et al., 2007). 
Complementing and confirming these findings, a contemporaneous report by Dina et al 
(Dina et al., 2007) took a different approach to discover this association, initially setting out 
to analyse the distribution of 48 neutral SNPs in a case-control obesity cohort collected from 
French individuals of European ancestry. While 47 of the 48 showed uniform distribution, 
the T allele of SNP rs 1121980 (located within the first intron of FTO) was strongly associated 
with severe adult obesity. Building upon this observation, Dina et al demonstrated several 
SNPs in the FTO locus to be highly associated not only with severe obesity in other adult, 
European populations but also with severe childhood obesity.  
The last of this triumvirate undertook a genome-wide association study in the genetically 
isolated population of Sardinia to identify genetic variants associated with obesity -related 
quantitative traits (Scuteri et al., 2007).  Again, a number of common variants in FTO were 
associated with BMI, hip circumference and total body weight. 
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The significant challenges were clear from the beginning. FTO was widely expressed 
throughout the body (Frayling et al., 2007) ;(Dina et al., 2007) ; (Gerken et al., 2007) and at 
the time nothing was know about function or potential pathways.  All of these initial reports 
made it clear that there was no ready mechanism to explain how the predisposing intronic 
variants affected function or expression of FTO. Indeed, right from the start there remained 
the  possibility that the underlying mechanism involved neighbouring genes or indeed other 
as yet to be identified genes more distant was raised 
However, hot on the heels of these initial findings, there followed a report which gave some 
important clues to FTO biology. Bioinformatics analysis indicated that FTO shared sequence 
motifs with Fe(II)- and 2-oxoglutarate–dependent oxygenases, with assays using 
recombinant murine Fto indeed showing that the protein could catalyze Fe(II)- and 2OG-
dependent DNA demethylation, the preferred substrate being 3-methylthymine in DNA. Fto 
was also found to be localised to the nucleus and highly expressed in hypothalamic regions 
with critical roles for the control of energy balance in a nutritionally dependent manner 
(Gerken et al., 2007). 
Subsequently, GWAS studies for obesity-related traits in a myriad of  European ancestry 
populations  confirmed that multiple SNPs at the FTO locus were associated with BMI (Graff 
et al., 2013); (Bradfield et al., 2012); (Lindgren et al., 2009); (Meyre et al., 2009); (Scherag et 
al., 2010); (Speliotes et al., 2010); (Thorleifsson et al., 2009); (Wheeler et al., 2013); (Willer 
et al., 2009).  Many other reports found the association of FTO SNPs with BMI in non-
European derived populations, including most populations of Asian ancestry, as well as 
Hispanic/Latino populations and  Pima Indians (reviewed by (Loos and Yeo, 2014)). 
Studies in populations of African ancestry, in which the FTO gene shows significant 
differences in allele frequency and linkage disequilibrium (LD) patterns, have proven to be 
insightful. Although several of the previously identified variants appear not to have 
significant association with BMI in these populations, other intronic variation around the 
FTO locus (such as rs3751812, rs9941349) show strong evidence of association (Adeyemo et 
al., 2010) ; (Hassanein et al., 2010). Further, the most significant value in the report by 
Peters et al.  came from a SNP (rs56137030 ) had not been highlighted in previous studies. 
(Peters et al., 2013). A recent meta-analysis by Monda et al. of data derived from 
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populations of African ancestry also provided  support for shared BMI loci across 
populations (Monda et al., 2013). 
The association of FTO SNPs with obesity related traits in children and adolescents was also 
extended (Bradfield et al., 2012); (Meyre et al., 2009); (Scherag et al., 2010). While SNPs in 
FTO did not influence birth weight (Horikoshi et al., 2013); (Jess et al., 2008); (Kilpelainen et 
al., 2011a), longitudinal studies revealed the effect  on body weight appeared during early 
childhood, reaching its peak at  young adulthood (Graff et al., 2013); (Hardy et al., 2010); 
(Sovio et al., 2011). 
This initial wave of association studies was soon followed by reports considering whether 
FTO SNPs associated with more specific regulators for energy homeostasis such as food 
intake or physical activity.  
Data pointing to a link with food intake began to emerge. Obesity-associated  FTO SNPs 
were found to be associated with increased energy intake (Cecil et al., 2008); (Speakman et 
al., 2008); (Timpson et al., 2008), increased intake of dietary fat (Park et al., 2013);  (Timpson 
et al., 2008) or protein (Sonestedt et al., 2009), increased appetite and reduced satiety 
(Wardle et al., 2008); (Wardle et al., 2009) and loss of control over eating (Tanofsky-Kraff et 
al., 2009).  This link with food intake was not seen in every study with, for example,  a report 
by Stutzmann et al. failing to find an association of the FTO rs 1421085 C  allele with eating 
behavious traits in a large European cohort of children and adults (Stutzmann et al., 2009) 
However, a recent GWAS of macronutrient intake in more than 70,000 individuals identified 
the BMI-increasing allele of FTO SNPs to be highly significantly associated with increased 
protein intake (Tanaka et al., 2013). 
Other studies have consistently shown that FTO SNPs are not associated with physical 
activity levels (Ahmad et al., 2010); (Franks et al., 2008); (Speakman et al., 2008); 
(Vimaleswaran et al., 2009). However, low physical activity has been reported to accentuate 
the  effect of FTO risk alleles on obesity in French adults  (Cauchi et al., 2009) with a large-
scale meta-analysis of published and unpublished data of more than 200,000 adults and 
20,000 children (Kilpelainen et al., 2011b) concluding that the association of FTO SNPs with 
the odds of obesity are reduced by close to a third in physically active adults. Phenotypic 
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variability in BMI for a given FTO genotype was also reported by Yang et al (Yang et al., 
2012) highlighting the potential of environmental modifiers to influence the ‘genetic 
burden’ of the FTO risk alleles. 
 
Model organisms and  Fto 
The phenotype of mice with a global, germline loss of Fto was first reported in 2009 (Fischer 
et al., 2009). Fto null mice suffered from a high perinatal mortality and a postnatal period 
characterised by reduction in both body length and body weight, the latter being a result of 
reduced fat and lean mass. They were reported to have both an increase in food intake and 
an increase in metabolic rate. Later analyses of several independent murine models of Fto 
loss also confirmed this pattern of post-natal growth retardation but one report has shown 
that when corrected for alteration in body composition, there was no difference in energy 
expenditure in mice globally lacking Fto (McMurray et al., 2013).  
 
In 2010, Cox and colleagues in Harwell generated mice globally expressing additional copies 
of the Fto gene (Church et al., 2010). This ubiquitous overexpression of Fto increased body 
and fat mass, with the obese phenotype more marked on a high-fat diet. Food intake was 
significantly increased, but energy expenditure and physical activity were unaltered in these 
mice.  
Reports of more specific regional and temporal Fto perturbation soon emerged. Gao et al. 
used a conditional allele to delete Fto in the nervous system (Gao et al., 2010). Their 
findings that this resulted in similar phenotypes as the whole body deletion pointed to Fto 
having a crucial role in the central nervous system to regulate postnatal growth. Following 
on from the finding that Fto expression in the arcuate nucleus of the hypothalamus was 
nutritionally regulated (Gerken et al., 2007); (Stratigopoulos et al., 2011); (Poritsanos et al., 
2011), we targeted this region with stereotactically delivered adeno-associated virus and 
demonstrated that overexpression decreased food intake, while knockdown of Fto 
increased food intake (Tung et al., 2010). 
McMurray also used a conditional allele to globally delete Fto at 6 weeks of age. 
Development in the weeks after was characterised by a loss of lean mass but an increase in 
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fat mass (McMurray et al., 2013). Intriguingly, regional deletion of Fto in mediobasal 
hypothalamus of adult mice did impact upon feeding behaviour but did not affect body 
composition, suggestive of Fto expressed in non-hypothalamic sites having a role in 
controlling lean mass. 
Thus, although many questions remained unanswered, from these animal data at least it 
seemed plausible that Fto had a role in the regulation of body composition and energy 
balance. 
Novel functions, unexpected roles. 
How then to try and link these murine and association studies with a common molecular 
mechanism, particularly one involving the demethylase activity reported by Gerken et al?  
(Gerken et al., 2007). The family of demethylase enzymes had long been known to have a 
role in repair of methyl lesions in DNA and RNA (Ougland et al., 2004); (Lee et al., 2005) but 
had little to directly link them to control of metabolism and body composition. Further 
studies followed that confirmed  FTO  catalyzed demethylation of 3-methylthymine in 
single-stranded DNA, as well as 3-methyluracil (3meU) (Gerken et al., 2007); (Jia et al., 2008) 
and 6-methyl adenosine (6meA) (Jia et al., 2011) in single-stranded RNA. 
The crystal structure of FTO was resolved and showed an N-terminal catalytic domain and a 
C-terminal domain of unknown function (Han et al., 2010). The specificity for single stranded 
nucleic acids appeared to come from an L1 loop, not present in other members of the AlkB 
family, which acted to hinder double stranded nucleic acids from entering the catalytic 
pocket (Han et al., 2010). 
The finding that  6meA, the most common modified nucleoside found in mRNA (Desrosiers 
et al., 1974), was demethylated by FTO with 50-fold greater affinity than 3meU (Jia et al., 
2011) gave rise to a hypothesis in which FTO influenced metabolism by  post transcriptional 
modification of RNA message. This idea was featured in two studies in 2013 (Hess et al., 
2013); (Karra et al., 2013) which explored how FTO’s putative demethylase action might 
affect complex human phenotypes. 
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Fto and dopamine 
Hess et al (Hess et al., 2013) described a role for Fto in controlling of the dopaminergic 
circuitry within the midbrain. The idea to explore a putative Fto-dopamine link came about 
because the phenotype of the Fto null mouse closely matched the description of mice 
lacking dopamine receptor type 2 (D2R; (Sibley, 1999)). Their studies found that Fto null 
mice responded differently to control animals after administration of cocaine, a drug which 
can inhibit the dopamine transporter and thereby increase synaptic dopamine levels. In 
response to cocaine, Fto-deficient mice failed to show an increase in locomotor activity, had 
less c-fos activation in the ventral tegmental area (VTA), caudate putamen (CPU) and 
nucleus accumbens (NAc) and had a blunted increase in extracellular dopamine. Further 
studies administering pharmacological agents know to act through the dopaminergic system 
to a range of genetically engineered animals confirmed that Fto loss impairs D2R-like 
signalling in a cell-autonomous manner. 
An elegant component to this story combined methylated RNA immunoprecipitation with 
bioinformatics to try and link these novel findings with previous data on the demethylase 
action of FTO. By identifying transcripts containing m6A in midbrains and striatum from 
control and Fto deficient mice, they found the transcripts selectively methylated in Fto null 
mice were disproportionately linked to synaptic transmission and cell signalling. Further, in 
the absence of Fto, both mRNA and protein of key regulators of dopaminergic neuron 
activity showed increased methylation.  
The identification of FTO specific adenosine methylation on a subset of mRNA involved in 
dopamine signalling pathway was the first in vivo demonstration of FTO as a functional m6A 
demethylase. These observations also provided the first indication that FTO may play a 
tissue or even cell-type specific role by regulating specific subsets of mRNA relevant to the 
physiological function of the tissue, and this might help explain how a single protein can 
appear to have such widespread influence over a range of seemingly disparate functions.  
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Ghrelin and the brain; is FTO the missing link ?  
The findings of the Hess study gave Fto a potential role in the reward systems. Following 
shortly after, a study by Karra et al. pursued a mechanistic link between FTO SNPs and gut 
peptides (Karra et al., 2013). They hypothesised that FTO variants might not only influence 
circulating levels of hormones known to have a role in appetitive behaviour but also that 
they might affect the neuronal response to food cues. 
Their  studies focused on small numbers of young, normal weight volunteers divided into 2 
matched groups on the basis of their genotype at the rs9939609 locus, either A/A (high risk) 
or T/T ( low risk).  Compared to TT subjects, after a test meal the AA group were reported to 
have a less marked fall in acyl ghrelin and an attenuated suppression in a visual analogue 
hunger score.  
Analysis of mRNA from peripheral blood cells after a period of  fasting was showed that 
subjects with the  AA genotype had, in comparison to the TT group,  a 1.5 fold increase in 
FTO expression, a 2.5 fold increase in ghrelin precursor GHRL mRNA abundance and a 
reduction in  m6 A methylation of ghrelin mRNA. Functional MRI (fMRI) analysis showed 
between-genotype differences in a number of brain regions recognised to have roles in 
energy homeostasis and reward related activity. 
A further potential link to ghrelin was suggested by data from in vitro studies, where FTO 
overexpression increased not only ghrelin and ghrelin O-acyltransferase (GOAT) mRNA but 
also total and acyl ghrlein concentrations in cell lysates. FTO overexpression was also 
reported to reduce m6 A methylation of ghrelin mRNA. 
These data lead the authors to the suggestion that the association of FTO risk allele with 
food intake may be mediated through ghrelin, with the risk allele increasing FTO expression 
which in turn reduces m6A ghrelin mRNA demethylation and thereby alters ghrelin 
production. The differential responses on fMRI observed in subjects with single nucleotide 
polymorphism were certainly striking  because such  phenomenon have only been 
demonstrated previously in situation with drastic physiological difference (De Silva et al., 
2012) such as comparing lean vs. obese individuals, between fed vs. fasted state or when 
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exogenous administration of appetite modulating hormones (e.g., Ghrelin, PYY, GLP-1 and 
leptin). 
While this work is of interest it is worth noting that leucocytes are not recognised as the 
natural home for understanding gut hormone biology and the sizeable changes in mRNA 
levels in white cells were not reflected in differences in the amount of circulating active acyl-
ghrelin  seen in the fasted state. Although there are measurable relative changes in white 
cell levels, the absolute contribution from these cells to total biological active ghrelin may 
not be large. It remains to be determined how, if at all, risk genotype affects ghrelin 
expression and production in the stomach and whether what is happening in a leucocyte 
bears any relationship to what might be happening within the antrum of the stomach. 
Additionally, it is worth noting that several studies have failed to reveal any influence of the 
FTO genotype on mRNA level of FTO, although mRNA expression of FTO in adipose tissue 
have been shown to be greater in obese individuals, this difference did not extend to FTO 
expression in blood cells. The fact that mice globally lacking Fto have unchanged levels of 
acylated ghrelin in both the fed and fasted state also suggests Fto levels contribute little to 
circulating  levels of ghrelin. 
 
Loss-of -function mutations in humans  
Despite all these emerging data, there remained the recurring uncertainty of what these 
findings brought to our greater understanding of human disease, the primary driver for 
undertaking the genetic studies in the first place. 
Important data on the potential consequences of FTO loss in humans came from a study of a 
consanguineous family in which affected individuals presented with a previously unreported 
autosomal-recessive syndrome characterised by polymalformation and childhood mortality 
(Boissel et al., 2009) . Genome-wide autozygosity screening identified a unique region of 
shared homozygosity on chromosome 16q12. Further genotype and haplotype analyses 
reduced the critical region to a 6.5Mb interval encompassing 28 genes. After sequencing 
coding regions and splice junctions of all known and putative genes in this linked region, the 
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only mutation found was a homozygous single-nucleotide variation at cDNA position 947 
within the FTO gene. Affected individuals carried a homozygous R316Q mutation in FTO, 
with loss  of this highly conserved arginine residue rendering FTO enzymatically null in two 
different  in vitro assays; the first based on the  conversion of the  2-oxoglutarate to 
succinate and the second on the ability of FTO to demethylate 3-methylthymine in DNA. The 
affected individuals homozygous for a catalytically inactive FTO also had, like Fto null  mice, 
an early growth retardation phenotype but, unlike the Fto null mice, also had 
developmental abnormalities in the central nervous or cardiovascular systems. These 
differences are not readily explained and the molecular mechanisms whereby the mutant 
FTO leads to the severe phenotype observed these patients remain unknown. However, it 
may be the point mutation in FTO has deleterious “gain-of-function” effects and/or 
dominant-negative interference with other biochemical processes that are not seen with 
the complete deficiency seen in Fto null mouse.  
What of other members of this extended family?  Fto +/- mice were considered to be 
resistant to diet induced obesity (Fischer et al., 2009), so could heterozygous carriage of this 
deleterious R316Q mutation actually protect against obesity?  This also remains uncertain 
because, although this report comments that none of the parents of affected children, 
obese but detailed phenotypic data on the extended family has not been reported. 
Other studies have gone on to look whether nonsynonymous variants of FTO might be 
enriched in either lean or obese subjects. Meyre et al.  sequenced entire FTO coding regions 
in  both subjects with severe obesity and in individuals with lifelong leanness (Meyre et al., 
2010) .Interestingly, non-synonymous mutations were equally common in both the obese 
and lean cohorts. Further, heterozygous mutations that severely impaired enzymatic activity 
of FTO were found in both lean and obese subjects who were otherwise clinically 
unremarkable. 
Other studies in lean and obese cohorts of children brought similar findings. In both African 
American and  Chinese Han populations, variants were identified in FTO but the overall 
frequencies were similar in case and control with none conferring risk of  obesity (Deliard et 
al., 2013);  (Zheng et al., 2013).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
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Taken in isolation, these human data fall some way short of a compelling case for FTO being 
the candidate mediator of the obesity association. Murine data indicate that an increase in 
Fto expression could potentially lead to obesity but, to date, only deleterious point 
mutations have been described in obese patients. However, it may be that there are as yet 
uncharacterised patients in other cohorts with genetically deleterious mutations leading to 
complete loss of FTO.  For example, such an individual may, if they were to phenocopy the 
mouse model of Fto deficiency, present initially as a “failure to thrive” and thereafter be 
noted to be of small stature. 
An interesting neighbourhood 
As outlined above, the initial FTO intronic associations, followed by identification of 
association SNPs in intron 3 (Tonjes et al., 2010) and intron 8 (Adeyemo et al., 2010), set in 
train a plethora of studies based around Fto biology. However, other groups took a different 
path, with the Leibel group in particular choosing to focus upon Rpgrip1l as being the 
potential mechanistic link. They initially took an in silico bioinformatics approach to focus on 
twointronic SNPs (rs17817449 and rs8050136) and predicted they were  located in a  
putative  binding site for the transcription factor Cutl-like 1 (CUTL1), also known as cut-like 
homeobox1 (CUX1) (Stratigopoulos et al., 2008). CUTL1 acts as a transcriptional repressor by 
displacing activators (Skalnik et al., 1991) and/or by recruitment of histone deacetylase 1 
(Mailly et al., 1996). Initial in vitro data were promising. In ChIP of DNA from human 
fibroblasts using a CUTL1-specific antibody, a 90-bp fragment that included rs8050136 was 
precipitated. Further, siRNA mediated reduction of Cutl1 by 70% resulted in FTO expression 
decreasing by 90% and FTM by 65%.   
Having raised the possibility that both genes were regulated by a CUTL1/CUX1 via a single 
regulatory site in the first intron of FTO, Leibel’s group went on to look in more detail at the 
role on the different isoforms of this transcription factor (larger P200 and the smaller p100 
isoform, generated from p200 by enzymatic cathepsin L activity)  (Stratigopoulos et al., 
2011). 
 A series of detailed biochemical and promoter analysis experiments lead to a proposed 
mechanism whereby together FTO, RPGRIP1L, and CUX1 facilitate the leptin response within 
the hypothalamic arcuate nucleus and thereby affect food intake. The model proposed that 
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reduced circulating leptin, as seen in negative energy balance, results in reduced enzymatic 
processing of CUX1 P200 and decreased CUX1 P110 protein levels. This change in 
transcription factor isoform ratio in turn decreases RPGRIP1L and FTO expression, reducing 
leptin signaling through an alteration in leptin receptor recruitment at the cilium and 
thereby increasing the drive to eat. The proposed model goes on to suggest that because 
P110 has reduced  affinity  for the rs8050136 obesity-risk (A) allele but  higher affinity for 
the protective (C) allele, individuals with the C allele would have higher FTO and RPGRIP1L 
expression and be relatively more leptin sensitive (Fig 1A) 
 
Building upon their previous findings, this group have more recently published a detailed 
metabolic phenotype of mice lacking one copy of Rpgrip1l (Stratigopoulos et al., 2014). As 
noted previously, homozygous mutations in Rpgrip1l lead to significant developmental 
anomalies (Vierkotten et al., 2007), but Rpgrip1l+/- mice had a small but statistically 
significant 10% increase in body weight demonstrable by 10 week (Fig 1B). Analysis of older 
animals showed this to be driven by increase in fat but not lean mass. By 19 weeks old, male 
mice had an increase in both fat and lean mass with absolute food intake corrected for 
different body compositions showing Rpgrip1l+/- to be hyperphagic. 
In Rpgrip1l+/- mice, an acute leptin dose was reported to show a diminished Stat 3 response 
within the hypothalamus and an antibody based analysis showed a reduction of leptin 
receptor in the vicinity of the cilia.   
This group went on to look at fibroblasts from healthy human controls and from a patient 
with Jouberts syndrome to furtherdetermine how RPGRIP1Linteracts with the leptin 
receptor. When leptin receptors were transfected into control fibroblasts, they correctly 
localized to the cilium with leptin stimulation and there was a dose dependent increase in 
Stats 3 phosphorylation.  In contrast there was both perturbed localisation and diminished 
signalling in RPGRIP1L deficient fibroblasts. 
They concluded that alteration in leptin receptors signaling brought about as a direct 
consequence of alteration in the function of primary cilium accounted for the increase in fat 
mass of Rpgrip1l+/- mice. These  model organism studies  are presented as further 
supportive evidence  that individuals  with obesity risk A allele at rs 8050136 have reduction 
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in both RPGRIP1L and FTO  expression due to reduction  on p110 at cognate CUX1 binding 
causing diminished leptin signalling, increased food intake and adiposity. 
Disorders of ciliary biology have long been linked to “syndromic obesity” and these data 
from the Liebel group now raise the intriguing possibility of primary cilia having a role in 
common forms of obesity. However, there remains still that elusive, direct connection 
between obesity associated variants and expression of the gene in question, in particular 
whether  in humans the number of copies of the risk allele associates with changes of 
expression of  RPGRIP1L and FTO  not only in the direction predicted by the model but also 
in physiologically relevant tissue.   
 
IRX3- another interesting neighbour. 
Irx3 was one of the initial genes identified within the Ft region, but initially did not attract as 
much attention as its neighbours. A report by Ragvin (Ragvin et al., 2010) re-ignited interest 
in its relationship with FTO. This group focussed in on the fact that the FTO LD block 
appeared to contain numerous highly conserved non coding elements (HCNEs) and used 
computational analysis to determine if these potential regulatory elements might affect 
target genes elsewhere. 
Their initial analysis suggested that the target gene of the HCNE within FTO was IRX3 and 
using sequences from the obesity associated FTO LD block in a zebrafish-based, GFP 
reporter assay found that expression patterns matched those of IRX3. As IRX3 is highly 
expressed in pancreas, they went on to suggest that at least some of the effect of the FTO 
locus upon susceptibility to type 2 diabetes may be through changes in insulin secretion. 
Smemo et al. build upon these observations  in a comprehensive study bringing together 
evidence from murine, human and in vitro studies  to make a compelling case for the 
involvement of IRX3 in the association between human obesity and FTO (Smemo et al., 
2014). 
They initially investigated cis-regulatory interactions between FTO and IRX3 using chromatin 
conformation capture in both embryonic (mice and zebrafish) and brain tissue from adult 
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mice. The authors found the promoter of Irx3 strongly interacted with the obesity-
associated interval within FTO (Fig 1A). 
Results from an  in vivo mouse reporter assay  which tested  human DNA fragments from 
the FTO obesity-associated region, plus data from studies using a human bacterial artificial 
chromosome (BAC) spanning the  FTO locus that included its promoter and the obesity-
associated region, clearly showed that IRX3 relied on long-range regulatory input from FTO. 
Building upon this, a crucial data set missing from previous studies looked at gene 
expression levels in the cerebellum, a site of high expression of both FTO and IRX3. This 
eQTL mapping in human brain samples demonstrated that obesity-linked SNPs such as 
rs9930506 were associated with IRX3 expression, but not with expression of FTO, thereby 
directly linking these variants to IRX3 regulation (Fig 1B).  
Returning to mouse models, Smemo reported that Irx3 null mice had a significant reduction 
in body weight, with less fat and lean mass compared to wild type controls. Transcriptional 
analysis of tissue indicated that there may be increased sympathetic tone to white adipose 
tissue as well as increased activation of brown adipose, leading to increased energy 
expenditure which contributes to the phenotype seen. Using Cre-lox technology to express a 
dominant-negative Irx3 only within the hypothalamus, this group determined that 
disrupting Irx3 function in this region alone recapitulated the metabolic phenotype of Irx3-
deficient mice, thereby supporting the notion that hypothalamic Irx3 to be critical in the 
regulation of body composition. 
While this appears to be a compelling set of data there are still some areas of uncertainty. 
Cerebellum is not an area of brain normally recognised to be involved in the control of 
energy expenditure and eQTL analysis using hypothalamic tissue seems to be an important 
next step. Further, it would be very interesting to determine if overexpression of Irx 3, 
either globally or in a more tissue specific manner, causes obesity in a model organism. 
Nevertheless, it would appear that IRX3 is a strong candidacy to be a major mediator of the 
effects of the common intronic SNPs on human adiposity.  
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Discussion 
The technological and computational advances that underpin genetic association  studies 
have brought forth a glut of new information relevant to a whole host of different human 
phenotypes, complex traits and disease conditions. They have much potential to reveal 
previously unanticipated insights but powerful as the data generated are, there remains the 
need to move from an association map into a systems, models and platforms that can be 
used as tools to get to grips with the biological architecture of the problem under scrutiny. 
So, seven years on from the initial cluster of reports, how far have we come with the poster 
boy of metabolic GWAS?  
The data set from animal studies make a decent case that FTO has a role in the control of  
energy homeostasis and body composition.  However, there is still much to learn. Whereas 
initial studies understandably focused on regions of the brain well characterised to have a 
role in energy balance, there remains uncertainty not only as to which brain regions are 
most critical but also what role Fto may play in peripheral tissues such as skeletal muscle 
and fat.  
Taken in isolation, the data on FTO from human studies fall some way short from making 
compelling case for FTO as a candidate mediator of the obesity association.  As described 
above, the most deleterious mutation has been identified in a single extended family with a 
multisystem phenotype that caused significant morbidity and early mortality. To date, there 
appears to be no reports of the deleterious encoding IRX3 mutations being found in 
populations of lean or obese; these would be a welcome addition to the field. 
Can we learn wider lessons on how to tackle the ever growing list of “hits” from 
metabolically relevant association studies? Although murine models have proven invaluable 
on the study of monogenic disorders of energy balance and appetitive behaviour, it is naïve 
to assume that murine models alone can give us all the answers. A comprehensive 
perspective which clearly lays out many of the issues surrounding the determination of 
pathogenicity (or otherwise) of genetic variance can be found in a recent article by 
MacArthur and colleagues, where the primacy of robust genetic support for causation is 
rightly emphasised (MacArthur et al., 2014). Further, the recent paper by Smemo 
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highlighting the role of IRX3 is an exemplar of how a multi-layered combination of 
techniques and evidence need to be marshalled together (Smemo et al., 2014).  The eQTL 
data presented are key pieces of evidence and in the future when determining if non-coding 
SNPs are exerting a functional impact through the alteration of gene expression, a stronger 
emphasis on eQTL mapping seems a sensible step forward.  Material contained with the 
GtEX dataset, for example, where a larger number of human tissues have been used for 
eQTL mapping (http://www.gtexportal.org/home/) is likely to be a valuable resource. 
Many of the strongest signals coming from GWAS spotlight genetic loci located some 
distance from coding exons. Sticking a pin in the nearest named coding sequence and 
studying the consequence of loss of that gene is one very simple way to move forward. But 
if we are to learn anything from the iterative process that the  FTO story has been to date, it 
is that it is only by embracing all the technologies at our disposal will we be able to move 
from GWAS signals to biological understanding . 
Figure 1. Increasing functional complexity around the FTO locus. 
A: emerging data indicate that the links between intronic variance within FTO and body 
composition are mediated through functional interactions with neighbouring genes.  The 
first intron of FTO contains a binding site for the transcription factor CUX1 which, through 
regulation of RPGRIP1L expression, modulates leptin receptor localisation within neurons.  
This intron also contains an enhancer sequence which directly binds to the promoter of 
IRX3. 
B: Summary of data on FTO, RPGRIP1L and IRX3 from human genetic and murine model 
studies. Data on IRX3 are notable in that that eQTL (expression quantitative trait loci) 
mapping demonstrates an association of obesity linked SNPS with IRX3 expression. 
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